{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:10:33Z","timestamp":1791036633191,"version":"4.1.0"},"reference-count":182,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.antiviral.2012.07.006","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T22:19:18Z","timestamp":1343254758000},"page":"36-50","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic vaccination against chronic hepatitis C virus infection"],"prefix":"10.1016","volume":"96","author":[{"given":"Peng Peng","family":"Ip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toos","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.07.006_b0910","first-page":"341","article-title":"Hepatitis C: global prevalence","volume":"72","author":"Anon","year":"1997","journal-title":"Wkly Epidemiol. Rec."},{"key":"10.1016\/j.antiviral.2012.07.006_b0915","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1086\/498218","article-title":"In vivo clearance of hepatitis C virus nonstructural 3\/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes","volume":"192","author":"Ahlen","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b0920","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.4049\/jimmunol.179.7.4741","article-title":"In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3\/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells","volume":"179","author":"Ahlen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0925","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","article-title":"Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial","volume":"16","author":"Alvarez-Lajonchere","year":"2009","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0930","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1016\/j.vaccine.2005.02.003","article-title":"Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus","volume":"23","author":"Arribillaga","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b0935","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.4049\/jimmunol.175.7.4686","article-title":"Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L","volume":"175","author":"Bachmann","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0940","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b0945","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0092-8674(01)00448-2","article-title":"Dendritic cells as vectors for therapy","volume":"106","author":"Banchereau","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2012.07.006_b0950","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b0955","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2893.2007.00934.x","article-title":"Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus","volume":"15","author":"Barnes","year":"2008","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0960","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2009.05.008","article-title":"Hepatitis C virus-induced hepatocarcinogenesis","volume":"51","author":"Bartosch","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0965","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/JVI.69.4.2462-2470.1995","article-title":"Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules","volume":"69","author":"Battegay","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0970","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.07.006_b0975","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2005-864786","article-title":"The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein\/F-protein, the double-frameshift protein, and others","volume":"25","author":"Branch","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b0980","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1099\/0022-1317-83-2-369","article-title":"Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles","volume":"83","author":"Brinster","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0985","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1099\/vir.0.008300-0","article-title":"Hepatitis C virus cell entry: role of lipoproteins and cellular receptors","volume":"90","author":"Burlone","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b0990","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(97)09440-3","article-title":"Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients","volume":"351","author":"Calarota","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.07.006_b0995","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques","volume":"80","author":"Capone","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1000","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.4049\/jimmunol.177.10.7462","article-title":"Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates","volume":"177","author":"Capone","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1005","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.4049\/jimmunol.1001114","article-title":"A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice","volume":"185","author":"Casares","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1010","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jgm.1407","article-title":"Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination","volume":"12","author":"Castellanos","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI117694","article-title":"Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif","volume":"95","author":"Cerny","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.07.006_b1025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni0104-7","article-title":"Dendritic cells: a journey from laboratory to clinic","volume":"5","author":"Cerundolo","year":"2004","journal-title":"Nat. Immunol."},{"issue":"Suppl. 3","key":"10.1016\/j.antiviral.2012.07.006_b1030","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1111\/j.1872-034X.2007.00220.x","article-title":"Regulatory T cells in hepatitis C virus infection","volume":"37","author":"Chang","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2012.07.006_b1035","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.4049\/jimmunol.1001790","article-title":"Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3\/4A-specific T cells during therapeutic vaccination","volume":"186","author":"Chen","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1040","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.07.006_b1050","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1016\/j.vaccine.2008.03.032","article-title":"A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection","volume":"26","author":"Chua","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/IAI.72.1.253-259.2004","article-title":"Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations","volume":"72","author":"Coban","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.antiviral.2012.07.006_b1060","doi-asserted-by":"crossref","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1065","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20050121","article-title":"Cellular immune selection with hepatitis C virus persistence in humans","volume":"201","author":"Cox","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coi.2009.01.010","article-title":"The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses","volume":"21","author":"Crawford","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri981","article-title":"Hepatic T cells and liver tolerance","volume":"3","author":"Crispe","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1080","first-page":"376","article-title":"Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response","volume":"119","author":"Dazert","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.07.006_b1085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jgm.1307","article-title":"Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development","volume":"11","author":"Desjardins","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hep.23980","article-title":"Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10","volume":"53","author":"Diaz-Valdes","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1095","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1128\/JVI.71.8.6011-6019.1997","article-title":"Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection","volume":"71","author":"Diepolder","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(95)91691-1","article-title":"Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection","volume":"346","author":"Diepolder","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.07.006_b1105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(96)00502-4","article-title":"DNA vaccines","volume":"60","author":"Donnelly","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.antiviral.2012.07.006_b1110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/COH.0b013e32834b87f8","article-title":"Future of hepatitis C therapy: development of direct-acting antivirals","volume":"6","author":"Dore","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2012.07.006_b1115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2012.07.006_b1120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2893.2007.00919.x","article-title":"The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies","volume":"14","author":"Dreux","year":"2007","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.24325","article-title":"Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells","volume":"54","author":"Echeverria","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2893.2008.01020.x","article-title":"Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)","volume":"15","author":"Echeverria","year":"2008","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jgm.1144","article-title":"Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model","volume":"10","author":"El-Gogo","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1140","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.3748\/wjg.v12.i44.7118","article-title":"Genetic vaccination with Flt3-L and GM-CSF as adjuvants: enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection","volume":"12","author":"Encke","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.2.2.2699","article-title":"DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model","volume":"2","author":"Encke","year":"2006","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.07.006_b1155","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","author":"Fafi-Kremer","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/sj.gt.3302754","article-title":"Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes","volume":"13","author":"Fattori","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1165","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.vaccine.2009.12.072","article-title":"Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine","volume":"28","author":"Firbas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1170","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1073\/pnas.230453597","article-title":"Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees","volume":"97","author":"Forns","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1175","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1016\/j.vaccine.2007.08.020","article-title":"An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses","volume":"25","author":"Fournillier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1180","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"Foy","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.07.006_b1185","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.07.006_b1190","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.gt.3302184","article-title":"Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3\/4A gene","volume":"11","author":"Frelin","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1200","doi-asserted-by":"crossref","first-page":"94ra71","DOI":"10.1126\/scitranslmed.3002330","article-title":"A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques","volume":"3","author":"Garrone","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1205","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/JVI.02053-07","article-title":"Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion","volume":"82","author":"Gastaminza","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jmv.20264","article-title":"Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein","volume":"75","author":"Gehring","year":"2005","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/CVI.00287-08","article-title":"Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles","volume":"16","author":"Gehring","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1220","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1478-3231.2007.01507.x","article-title":"Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile","volume":"27","author":"Gelderblom","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2012.07.006_b1225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/gt.2010.22","article-title":"Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine","volume":"17","author":"Gill","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1230","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1235","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1086\/383248","article-title":"Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection","volume":"189","author":"Goutagny","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b1240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1245","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.21376","article-title":"Hepatitis C virus reinfection in injection drug users","volume":"44","author":"Grebely","year":"2006","journal-title":"Hepatology"},{"issue":"890\u2013899","key":"10.1016\/j.antiviral.2012.07.006_b1250","first-page":"e891","article-title":"A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1255","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2006.10.035","article-title":"Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins","volume":"25","author":"Haller","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1260","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1073\/pnas.96.10.5692","article-title":"Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers","volume":"96","author":"He","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Pt 1","key":"10.1016\/j.antiviral.2012.07.006_b1265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1099\/0022-1317-80-1-187","article-title":"Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus","volume":"80","author":"Hiranuma","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1270","unstructured":"Inovio, 2010. Inovio Pharmaceuticals\u2019 Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio\u2019s Electroporation Delivery Technology, pp. Inovio Pharmaceuticals, Inc Web Site."},{"key":"10.1016\/j.antiviral.2012.07.006_b1275","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1280","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.vaccine.2009.10.150","article-title":"Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses","volume":"28","author":"Jirmo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1285","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1128\/JVI.78.13.7257-7263.2004","article-title":"Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity","volume":"78","author":"Keck","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1290","first-page":"398","article-title":"Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan","volume":"52","author":"Khattak","year":"2002","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.antiviral.2012.07.006_b1295","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1053\/j.gastro.2010.09.042","article-title":"Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes","volume":"140","author":"Kim","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1300","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1305","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/IAI.67.11.5658-5663.1999","article-title":"Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection","volume":"67","author":"Klinman","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.antiviral.2012.07.006_b1310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00870272","article-title":"DNA vaccines: safety and efficacy issues","volume":"19","author":"Klinman","year":"1997","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1315","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/JVI.70.1.232-240.1996","article-title":"Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region","volume":"70","author":"Kurokohchi","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1320","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2005\/617326","article-title":"The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia","volume":"16","author":"Kuyper","year":"2005","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1325","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2005.10.048","article-title":"Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens","volume":"130","author":"Kuzushita","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1330","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2010.04.033","article-title":"Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens","volume":"28","author":"Lambeck","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1335","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/j.gastro.2004.06.015","article-title":"High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection","volume":"127","author":"Lauer","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1340","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1350","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1084\/jem.191.9.1499","article-title":"Analysis of successful immune responses in persons infected with hepatitis C virus","volume":"191","author":"Lechner","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2010.02.003","article-title":"Development of novel therapies for hepatitis C","volume":"86","author":"Lemon","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.07.006_b1360","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1365","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.3748\/wjg.v12.i44.7126","article-title":"Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models","volume":"12","author":"Li","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1370","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1128\/JVI.02743-07","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1375","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.07.006_b1380","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1385","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1084\/jem.189.3.587","article-title":"CD8alpha+ and CD8alpha\u2212 subclasses of dendritic cells direct the development of distinct T helper cells in vivo","volume":"189","author":"Maldonado-Lopez","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1390","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.07.006_b1395","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2009.06.005","article-title":"Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein","volume":"51","author":"Mansilla","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1400","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/JVI.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase","volume":"69","author":"Mansky","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1405","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1410","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0264-410X(02)00704-1","article-title":"Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid","volume":"21","author":"Matsui","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1415","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.07.006_b1420","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.07.006_b1425","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/hep.24171","article-title":"In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus","volume":"53","author":"Meuleman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1430","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1435","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.4049\/jimmunol.1001877","article-title":"Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain","volume":"186","author":"Mikkelsen","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1440","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-1117-3","article-title":"Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses","volume":"10","author":"Mine","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2012.07.006_b1445","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/589510","article-title":"Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV","volume":"198","author":"Mizukoshi","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b1450","doi-asserted-by":"crossref","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2012.07.006_b1455","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-8-36","article-title":"Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines","volume":"8","author":"Naslund","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2012.07.006_b1815","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2004.12.018","article-title":"Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC)","volume":"42","author":"Nattermann","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1460","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.22242","article-title":"Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection","volume":"47","author":"Neumann-Haefelin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.20157","article-title":"Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients","volume":"63","author":"Noguchi","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.antiviral.2012.07.006_b1470","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"Ogata","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1475","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1480","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1016\/j.vaccine.2008.05.017","article-title":"Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys","volume":"26","author":"Park","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1485","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.amjmed.2004.03.024","article-title":"Hepatitis C treatment update","volume":"117","author":"Pearlman","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1490","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1495","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.07.006_b1500","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.07.006_b1505","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1510","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization","volume":"85","author":"Prentoe","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1515","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.vaccine.2008.07.034","article-title":"Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants","volume":"26","author":"Qiu","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1520","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1074-7613(03)00353-4","article-title":"Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity","volume":"20","author":"Racanelli","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.07.006_b1525","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.74.2.923-933.2000","article-title":"Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine","volume":"74","author":"Ramirez","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1530","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b1535","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence","volume":"119","author":"Rehermann","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.07.006_b1540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1545","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.gt.3302536","article-title":"Induction of human papilloma virus E6\/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6\/E7-transgenic mice","volume":"12","author":"Riezebos-Brilman","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1550","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/sj.gt.3303036","article-title":"A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer","volume":"14","author":"Riezebos-Brilman","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1555","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1086\/432517","article-title":"Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting","volume":"192","author":"Rollier","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b1560","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1565","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature07106","article-title":"Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA","volume":"454","author":"Saito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.07.006_b1570","doi-asserted-by":"crossref","first-page":"11803","DOI":"10.1128\/JVI.00997-08","article-title":"Escape from HLA-B\u221708-restricted CD8 T cells by hepatitis C virus is associated with fitness costs","volume":"82","author":"Salloum","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1575","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2012.07.006_b1580","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2007.06.026","article-title":"Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients","volume":"25","author":"Schlaphoff","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1585","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI119149","article-title":"Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity","volume":"99","author":"Schulick","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2012.07.006_b1590","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.4049\/jimmunol.158.11.5087","article-title":"Microbial products induce autoimmune disease by an IL-12-dependent pathway","volume":"158","author":"Segal","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1595","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/blood-2005-11-4522","article-title":"Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy","volume":"107","author":"Semmo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2012.07.006_b1600","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/vim.2006.19.702","article-title":"Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes","volume":"19","author":"Shi","year":"2006","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1605","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.4049\/jimmunol.154.6.2733","article-title":"CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1","volume":"154","author":"Shirai","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1610","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/87974","article-title":"Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity","volume":"7","author":"Stubbs","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1615","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"Sumida","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1620","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1625","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1630","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1073\/pnas.202608299","article-title":"Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease","volume":"99","author":"Thimme","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1515\/BC.2008.061","article-title":"Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine","volume":"389","author":"Thimme","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2012.07.006_b1640","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1645","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20041006","article-title":"CD8 epitope escape and reversion in acute HCV infection","volume":"200","author":"Timm","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.07.006_b1650","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1389450043490677","article-title":"Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy","volume":"5","author":"Torresi","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.antiviral.2012.07.006_b1655","doi-asserted-by":"crossref","first-page":"e1000143","DOI":"10.1371\/journal.ppat.1000143","article-title":"Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness","volume":"4","author":"Uebelhoer","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2012.07.006_b1660","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.07.006_b1665","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.21242","article-title":"Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses","volume":"44","author":"Urbani","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1670","doi-asserted-by":"crossref","first-page":"12423","DOI":"10.1128\/JVI.76.24.12423-12434.2002","article-title":"Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C","volume":"76","author":"Urbani","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1675","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0105-2896.2006.00379.x","article-title":"Human virus-specific CD8+ T cells: diversity specialists","volume":"211","author":"van Leeuwen","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2012.07.006_b1680","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1685","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/infdis\/jir423","article-title":"Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies","volume":"204","author":"Verstrepen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.07.006_b1690","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/viro.2000.0566","article-title":"Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens","volume":"276","author":"Vidalin","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.07.006_b1695","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1021\/mp1002043","article-title":"Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine","volume":"8","author":"Walczak","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2012.07.006_b1700","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2249.2002.01840.x","article-title":"Cellular immune responses against hepatitis C virus: the evidence base 2002","volume":"128","author":"Ward","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1705","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.4049\/jimmunol.169.6.3447","article-title":"Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection","volume":"169","author":"Wedemeyer","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1710","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1073\/pnas.92.7.2755","article-title":"Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant","volume":"92","author":"Weiner","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.07.006_b1715","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1720","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2893.2009.01228.x","article-title":"Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells","volume":"17","author":"Wintermeyer","year":"2010","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1725","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00535-007-2057-5","article-title":"Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments","volume":"42","author":"Wintermeyer","year":"2007","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1730","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.07.006_b1735","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.vaccine.2004.01.048","article-title":"Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice","volume":"22","author":"Wuest","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1740","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0928-4346(96)82012-3","article-title":"Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992","volume":"5","author":"Xia","year":"1996","journal-title":"Int. Hepatol. Commun."},{"key":"10.1016\/j.antiviral.2012.07.006_b1745","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/vim.2006.19.210","article-title":"Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3","volume":"19","author":"Xiang","year":"2006","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1750","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2012.07.006_b1755","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1371\/journal.ppat.0030108","article-title":"Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus","volume":"3","author":"Ye","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2012.07.006_b1760","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.79821-0","article-title":"Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3","volume":"85","author":"Yu","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1765","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.vaccine.2006.11.046","article-title":"Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3\/4A mRNA","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1770","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2893.2008.00959.x","article-title":"Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity","volume":"15","author":"Yu","year":"2008","journal-title":"J. Viral Hepatol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1775","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1349-7006.2009.01256.x","article-title":"Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles","volume":"100","author":"Yutani","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.antiviral.2012.07.006_b1780","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1016\/j.vaccine.2007.08.005","article-title":"Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy","volume":"25","author":"Yutani","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2012.07.006_b1785","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2007.01.001","article-title":"Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40","volume":"74","author":"Zabaleta","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.07.006_b1790","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.mt.6300333","article-title":"Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein","volume":"16","author":"Zabaleta","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2012.07.006_b1795","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.3748\/wjg.v13.i36.4824","article-title":"Neutralizing antibodies in hepatitis C virus infection","volume":"13","author":"Zeisel","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1800","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3748\/wjg.v10.i17.2488","article-title":"A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses","volume":"10","author":"Zhu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1805","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1128\/CVI.00490-09","article-title":"The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB\/c mice","volume":"17","author":"Zhu","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2012.07.006_b1810","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.vaccine.2009.02.045","article-title":"T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation","volume":"27","author":"Zubkova","year":"2009","journal-title":"Vaccine"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T13:06:50Z","timestamp":1714223210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":182,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0166354212001672"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.07.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}